An 8 week open-label interventional multicenter study to explore the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥8 years of age, chronically infected with Pseudomonas aeruginosa.
Sivagurunathan SutharsanSusanne NaehrigUwe MelliesChristian SiederJörg ZieglerPublished in: BMC pulmonary medicine (2020)
The study is registered with ClinicalTrials.gov, identifier: NCT02248922.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- clinical trial
- open label
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- randomized controlled trial
- phase ii
- squamous cell carcinoma
- radiation therapy
- chronic obstructive pulmonary disease
- drug resistant
- patient reported outcomes
- acinetobacter baumannii
- rectal cancer
- patient reported